You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中恆集團(600252.SH)擬變更7.32億元募集資金用途 用於擬認購萊美藥業股份
格隆匯 02-22 17:57

格隆匯2月22日丨中恆集團(600252.SH)公佈,公司擬與南寧中恆同德醫藥產業投資基金合夥企業(有限合夥)(以下簡稱“中恆同德”)和廣西廣投國宏健康產業基金合夥企業(有限合夥)(以下簡稱“廣投國宏”)共同參與認購萊美藥業2020年度非公開發行A股股票。

公司於2021年2月19日召開第九屆董事會第二十二次會議,審議通過了《廣西梧州中恆集團股份有限公司關於變更部分募集資金用途暨關聯交易的議案》。本次變更募集資金將用於“參與認購重慶萊美藥業股份有限公司2020年非公開發行A股股票”項目,公司擬認購萊美藥業股份數量為2.11億股,出資金額為9.39億元,出資金額與本次變更用途募集資金的差額部分由公司以自有或自籌資金補足。本次變更的募集資金金額為7.32億元(最終剩餘募集資金金額以資金轉出當日募集資金專户餘額加上募集資金存款利息之和為準)。

公司根據實際情況和需要,可以自籌資金先行認購萊美藥業非公開發行的股票,後續經履行法定程序和內部決策程序後用募集資金予以置換。公司參與認購萊美藥業非公開發行A股股票項目,屬於主營業務投資,符合《上海證券交易所上市公司募集資金管理辦法》關於“變更後的募投項目應投資於主營業務”的有關規定。

目前,公司的核心業務板塊為中成藥製造和銷售,萊美藥業主要產品為化學藥和創新藥,通過參與萊美藥業非公開發行,可補充公司在化學藥和創新藥方面的短板,公司主營業務仍為醫藥製造板塊業務。由於近年來,醫藥行業受政策影響較大,若公司投資的萊美藥業在經營策略上不能及時調整,不能順應國家有關醫藥行業的產業政策和行業法規的變化,則可能對其生產經營構成不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account